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Hypoxia triggers IFN-I production 
in muscle: Implications in 
dermatomyositis
Noemí De Luna1, Xavier Suárez-Calvet1, Cinta Lleixà1, Jordi Diaz-Manera1, Montse Olivé2,3, 
Isabel Illa1 & Eduard Gallardo  1
Dermatomyositis is an inflammatory myopathy characterized by symmetrical proximal muscle 
weakness and skin changes. Muscle biopsy hallmarks include perifascicular atrophy, loss of 
intramuscular capillaries, perivascular and perimysial inflammation and the overexpression of IFN-
inducible genes. Among them, the retinoic-acid inducible gene 1 (RIG-I) is specifically overexpressed in 
perifascicular areas of dermatomyositis muscle. The aim of this work was to study if RIG-I expression 
may be modulated by hypoxia using an in vitro approach. We identified putative hypoxia response 
elements (HRE) in RIG-I regulatory regions and luciferase assays confirmed that RIG-I is a new HIF-
inducible gene. We observed an increase expression of RIG-I both by Real time PCR and Western blot in 
hypoxic conditions in human muscle cells. Cell transfection with a constitutive RIG-I expression vector 
increased levels of phospho-IRF-3, indicating that RIG-I promotes binding of transcription factors to 
the enhancer sequence of IFN. Moreover, release of IFN-β was observed in hypoxic conditions. Finally, 
HIF-1α overexpression was confirmed in the muscle biopsies and in some RIG-I positive perifascicular 
muscle fibres but not in controls. Our results indicate that hypoxia triggers the production of IFN-I in 
vitro, and may contribute to the pathogenesis of DM together with other inflammatory factors.
Dermatomyositis (DM) is an inflammatory myopathy affecting skin and skeletal muscle. The pathogenesis of 
DM is complex, comprising both immune and non-immune mechanisms. As in other inflammatory myopathies, 
expression of the major histocompatibility complex class I (MHC-I) is upregulated in the muscle fibres. Muscle 
biopsy findings in DM show complement deposition in the endothelium, and focal loss of capillaries1. In addition, 
it has been observed that neovascularization has a prominent role in DM2 maybe due to a compensatory mecha-
nism. It has been showed that capillary alterations in DM are consistent with whole microvascular units drop out 
rather than random capillary damage3, although a lesion upstream to capillaries has not been proven. However, a 
correlation between areas of capillary depletion and perifascicular atrophy has been observed4.
Tissues with impaired oxygen supply, produced by capillaries loss or clogging, show significant changes in 
gene expression, mainly modulated by hypoxia-inducible factor 1-alpha (HIF-1α) in a very dynamic process5. 
In normoxic conditions HIF-1α is constituvely hydroxylated. The prolyl hydroxylation represents a posttrans-
lational mechanism to regulate protein interactions. Hydroxylated HIF-1α is ubiquitinated and degradated via 
proteasome. In contrast, when oxygen is decreased, HIF-1α forms a heterodimer with HIF-1β, that escapes prolyl 
hydroxylation, and then translocates to the nucleus and binds to hypoxia-response elements (HRE) present in 
the regulatory regions of hypoxia-inducible genes6. These genes are involved in metabolic adaptation (glycogen 
synthase7), angiogenesis (VEGF), and intriguingly, inflammation8. Also, it has been shown that inflammatory 
cytokines (TNF-α and IL1β) can induce HIF-1α expression in rheumatoid synovial fibroblasts9.
Microarray studies of muscle biopsies from patients with DM have shown overexpression of IFN-I-inducible 
transcripts, such as interferon-inducible protein 15 (ISG15), Myxovirus resistance A (MxA), Signal Transducer 
and Activator of Transcription 1 (STAT1) and retinoic acid-inducible gene I (RIG-I), that were validated at the 
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protein level and specifically detected at perifascicular atrophic areas in DM muscle10–14. Interestingly, it has been 
shown that ISG15 bears HREs in its promoter and a negative feedback loop for HIF-1α in some cell lines has been 
proposed15. RIG-I is an innate immunity receptor of the retinoic acid-like receptors family and an IFN-stimulated 
gene itself16. Activation of RIG-I induces the signalling cascade that involves IRF3 and IRF7 phosphorylation17 
and consequently IFN-β expression18. Since capillary loss is observed in DM muscle we hypothesized that HIF-1α 
can be stabilized and therefore activate hypoxia inducible genes. Since our in silico analysis demonstrated that 
RIG-I contains HRE in its regulatory regions, we aimed to study if RIG-I expression may be regulated by hypoxia 
and the effects of that modulation using an in vitro approach.
Results
Putative hypoxia response elements (HRE) sequences identified in the human DDX58/RIG-I 
and OAS2 promoters. To investigate the possible effect of hypoxia in the transcriptomic induction of genes 
that belong to the IFN-I signature and previously related with DM12, 13, we searched for the presence of HRE in 
regulatory regions of those genes. Bioinformatic analysis using BLAST alignment tool showed the presence of 4 
HRE in the 3′UTR region of DDX58/RIG-I (NM_014314.3) (+3470, +3676 +3834, +3892) (Fig. 1). OAS2 has 
one HRE in 3′UTR (+2615) (NM_002535 numbered from ATG). In contrast, we did not find any HRE motifs in 
the regulatory regions of TLR3, RNASEL, OAS1, OAS3, β-2-microglobulin a subunit of MHC-I, IFN-α, IFN-β and 
IFN-γ genes. It has been previously described that ISG15 has four HREs in 5′UTR15.
Figure 1. Nucleotides sequences of the cloned fragments of RIG-I 3′UTR and IFN-β enhancer. Sequences of 
primers used and regulatory elements are highlighted in different colours.
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3′UTR region of RIG-I is activated under chemically-induced hypoxia. We next addressed the 
responsiveness of the HRE motifs present in the RIG-I 3′UTR region under hypoxic conditions. We performed a 
functional study using a pGL3p luciferase reporter plasmid including the 580 bp RIG-I 3′UTR fragment that con-
tains four HRE motifs. Luciferase assays demonstrated a significant increase in firefly/renilla luminescence ratio 
under hypoxia compared to normoxia (p < 0.05). We mutated this vector and deleted all HREs (pGL3p + RIG-I 
3′UTR ΔHRE) to analyze luciferase activation under hypoxia. We did not find significant differences in the 
induction of luciferase when no HREs were present in the construct in hypoxia compared to normoxia (Fig. 2).
Hypoxia induces the expression of DDX58/RIG-I expression in human myotubes. Our luciferase 
studies in HEK cells showed that RIG-I transcription is activated under chemically-induced hypoxia with CoCl2. 
We next analyzed if RIG-I expression was induced in human myotubes after both chemically-induced hypoxia 
(CoCl2) and low levels of O2. Indeed, a significant increased expression of RIG-I mRNA was observed when 
human myotubes were cultured in a hypoxic chamber at a 1% concentration of O2 compared to normoxia. Same 
results were observed in CoCl2 treated cultures (Fig. 3A). In normoxia, levels of RIG-I mRNA remained at low 
levels at all the time points analyzed. These results were confirmed by WB, showing an increased expression of 
RIG-I when HIF1α expression was increased due to its stabilization (Fig. 3B), either by low levels of O2 or by 
CoCl2 induced hypoxia.
IFNs do not stabilize HIF-1α in human myotubes. Our results have shown that RIG-I is a 
hypoxia-inducible gene in addition to be a known interferon-inducible gene. To exclude the possibility that 
HIF1α stabilization is directly induced by IFN-I we cultured human primary myotubes with IFN-α or IFN-β 
and analysed HIF1α expression by WB. No HIF expression was observed 24 and 48 h after stimulation with IFNs. 
However, we found an upregulation of RIG-I at 24 h and 48 h (Fig. 4) after stimulation with 100 U/ml of either 
IFN-α or IFN-β. We confirmed the effect of IFNs by analyzing the translocation of STAT-1 to the myonuclei by 
immunocytochemistry (data not shown). These results indicate that in our cell model the expression of RIG-I can 
be induced directly by hypoxia independently of IFN-I.
RIG-I overexpression leads to downstream activation of IFN type I signalling. We reproduced 
in vitro the overexpression of RIG-I previously observed in DM biopsies to investigate its functional conse-
quences. We focused on the induction of RIG-I signalling through IRF3 phosphorylation that eventually pro-
motes IFN-I production. Transfection of HEK-293 cells with a vector that leads to constitutive expression of 
RIG-I (pCMV-RIG-I) increased levels of IRF3-P both in normoxia and hypoxia compared to non-transfected 
cells (Fig. 5A). Cells transfected with a non-related vector expressing contactin-1 constitutively (pCMV-CNTN1) 
had no effect on IRF3 phosphorylation. These results suggest that overexpression of RIG-I per se induces IFNs 
signalling pathway and prompted us to hypothesize that high amounts of RIG-I would lead to a higher transcrip-
tion of IFN-β. To test this hypothesis, we transfected HEK-293 cells with pCMV-RIG-I together with pGL3b-IFN 
enhancer. Luciferase assay showed an increased of firefly/renilla luciferase ratio (p < 0.001) (Fig. 5B), indicating 
that RIG-I promotes binding of transcription factors (e.g.IRF3-P) to the consensus sequences in the enhancer of 
IFN.
Skeletal muscle cultures under hypoxic conditions release IFNβ. We measured IFN-β release from 
myotubes cultures at low levels of oxygen (1%) and CoCl2 treated cultures compared to those grown in normoxia. 
Under normoxia no IFNβ was detected in the supernatants at any of the time points analyzed. Under hypoxic 
conditions, no IFN-β was detected after two hours. However, in CoCl2 treated-cultures during 4 h and 24 h, IFN-β 
concentration was 1.4 ± 0.2 pg/ml and 1.5 ± 0.6 pg/ml. These results were confirmed in muscle cell cultures under 
1%O2 at the same time points. The concentration of IFN-β in supernatants was 1.5 ± 0.8 pg/ml and 1.9 ± 0.8 pg/
ml respectively. No IFN-α was detected in the supernatant of either cultures in normoxia or in hypoxia.
Figure 2. Analysis of the induction of RIG-I transcription by luciferase assays. Transfection of HEK-293 cells 
with pGL3p-RIG-I 3′UTR cultured in chemically -induced hypoxia (CoCl2) induces a significant increase in 
firefly/renilla luminiscence ratio compared to the same transfected HEK-293 cells cultured in normoxia. No 
differences were observed when no HREs were present in the plasmid (with pGL3p-RIG-I ΔHRE). Three 
independent experiments were performed for each condition. Error bars reflect SD. *p < 0.05.
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HIF-1α expression in the muscle biopsies from DM patients. We observed the expression of HIF-1α 
and RIG-I in all muscle biopsies from DM patients with a similar immunostaining pattern whereas control mus-
cle biopsies were negative (Fig. 6). Although some perifascicular atrophic fibres were positive for both RIG-1 and 
HIF-1α, we found muscle fibres positive for HIF-1α but not for RIG-I.We also observed HIF-1α positive fibres in 
intrafascicular areas (Fig. 6). STAT1, another IFN-I signature protein, was also expressed in perifascicular areas 
that were positive for HIF-1α (Fig. 6). We used muscle cells cultured with CoCl2 as a positive control for HIF-1α 
staining and HEK cells transfected with pCMV-RIG-I as a positive control for RIG-I staining (Fig. 7).
Figure 3. RIG-I is overexpressed in a HIF-dependent manner. (A) No DDX58/RIG-I mRNA was observed 
in normoxic conditions. RIG-I was increased both in hypoxia (1%O2) and in chemically-induced hypoxia 
(250 μM CoCl2). At 2 hours of hypoxia induction, RIG-I expression was higher under low levels of O2 than 
after chemically-induced hypoxia. (B) RIG-I expression also increases under different hypoxic conditions. 
Maximum levels of RIG-I were obtained after 2 h with low levels of O2. In chemically-induced hypoxia RIG-I 
overexpression was higher after 4 hours of CoCl2 treatment. Three independent experiments were performed. 
Error bars reflect SD. *p < 0.05; **p < 0.01, ***p < 0.001, ****p < 0.0001.
Figure 4. IFN-β stimulation of human myotubes induces RIG-I expression but not HIF-1α stabilization. 
Human primary myotubes were stimulated with 100 U/ml of IFN-α or IFN-β, during 48 h. Lane1: Myotubes 
cultured in normoxic conditions; Lane 2: 250 μM CoCl2-treated cultures; Lane 3 IFN-α treated cultures; Lane 4 
IFN-β treated cultures. Lanes were run in the same gel but were noncontiguous. Three independent experiments 
were performed.
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Discussion
We demonstrate herein that hypoxia induces RIG-I overexpression in human myotubes through HIF-1α sta-
bilization. We show that high levels of RIG-I induce the signalling cascade that activates the transcription of 
IFN-I and we report the expression of HIF-1α in muscle fibers in DM. We have also shown in vitro that human 
myotubes under hypoxic conditions release IFN-β to the supernatant. We found that the 3′UTR regulatory region 
of the RIG-I promoter contains HREs, and firefly/renilla assays demonstrated that RIG-I is a newly described 
HIF-inducible gene. The experiments in which we removed the HREs present in 3′UTR of RIG-I gene confirmed 
the need of these regulatory regions to induce its transcription under hypoxia.
The expression of RIG-I observed in DM muscle can be induced by IFN and our results demonstrate that 
hypoxia can also induce RIG-I in vitro. We cannot exclude the possibility that in DM, HIF-1α stabilization could 
be regulated by other factors such as inflammatory cytokines in addition to hypoxia19. Although we demonstrated 
in vitro that the overexpression of RIG-I induces the production of IFN-I, it is difficult to establish the sequential 
activation of secondary messengers in IFN-I signalling pathway in vivo.
Although some atrophic fibres were positive for both RIG-I and HIF-1α, we found perifascicular fibres pos-
itive for HIF-1α but not for RIG-I. The presence of HIF-1α and RIG-I in the muscle biopsies of DM can be 
explained by either an inflammatory environment or a hypoxic process. In fact, HIF-1α expression is not confined 
to perifascicular areas. In the same way, it has been reported that hypoxia inducible proteins accumulate mostly 
in DM20, 21. Expression of STAT1 in perifascicular fibres of DM biopsies is a hallmark of a IFN-I response in this 
disease10, 12. And in fact, we have observed that some perifascicular HIF-1α -positive fibres also express STAT1. 
We believe that not all STAT1 and/or RIG-I positive fibres are also positive for HIF-1α because the muscle biopsy 
limits us to analyze the situation at a given time point. HIF-1α has been considered as a transcriptional regulator 
of immunity and inflammation22 and, indeed, some diseases such as rheumatoid arthritis, present high levels of 
HIF-123. HIF-1α is known to regulate the expression of more than 100 genes that function in a variety of cellular 
stress responses triggered by low levels of oxygen22. This situation may occur in DM muscle where the number 
of capillaries is compromised. Accordingly, hypoxia enhances the expression of RIG-I in human myotubes. No 
significant differences in RIG-I expression and IFN-β release were observed between cultures grown in hypoxic 
environment in a hypoxic chamber and the hypoxia induced in CoCl2 treated cultures, which have the advantage 
of being inexpensive, fast and allows free manipulation of cell cultures without affecting hypoxic conditions24.
We did not observe HIF-1α stabilization when we cultured myotubes with IFNs although it has been described 
in other cellular models9. Our results show that the overexpression of RIG-I triggers IRF3 phosphorylation and 
Figure 5. RIG-I overexpression induces IFN-β transcription. (A) HEK-293 cells were transfected with a 
pCMV-RIG-I vector which constitutively expressed RIG-I. RIG-I expression induced phosphorylation of IRF-3, 
an intermediate effector of IFN-β signalling, both in normoxia and hypoxia at 48 h and 72 h. (B) Co-transfection 
of HEK-293 with pGL3b-IFN-β enhancer and pCMV-RIG-I showed an increased luciferase signal, indicating 
activation of IFN-β transcription when RIG-I is overexpressed. *p < 0.05; **p < 0.01. Error bars reflect SD. Four 
independent experiments were performed.
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IFN-β transcription per se. Interestingly, it has been reported that RIG-I is also overexpressed in the hippocampus 
after focal cerebral hypoxia25.
In terms of biological significance, pattern recognition receptors must be expressed to control the sterile 
inflammation response in a hypoxic microenvironment where danger-associated molecular patterns (DAMPs) 
are released26. In heart tissue, it has been reported that extracellular RNA released due to hypoxia and I/R injury 
activates innate immunity TLR3-Trif signalling and contributes to myocardial inflammation27. In animal models 
of hepatic I/R injury, it has been shown that damage was significantly decreased when the experiments were per-
formed in both, IFN-I receptors and in IRF3-deficient animals28, 29. These results support that IFN-I production 
can be modulated by I/R tissue injury. However in the present study we have not studied the possible release of 
DAMPs under hypoxia, further studies are needed to demonstrate the presence of DAMPs in DM.
In summary, our results indicate that hypoxia triggers the production of IFN-I in vitro, and may contribute to 
the pathogenesis of DM together with other inflammatory factors.
Material and Methods
Patients. All patients (n = 10) were diagnosed of adult DM according to established clinicopathological crite-
ria30. For more information, see material and methods section in SI. All muscle biopsies presented perifascicular 
Figure 6. HIF-1α is overexpressed in muscle biopsies from DM patients. Double immunofluorescence show 
that HIF-1α is present mostly in perifascicular atrophic fibres and some of them are also positive for RIG-I and 
STAT1. Control muscle biopsies are negative for HIF-1α, RIG-I and STAT1. Magnification ×200.
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atrophy and membrane attack complex deposits in vessels, muscle fibres or both. All patients signed an informed 
consent and the project was approved by the Ethics Committee at Hospital de la Santa Creu i Sant Pau (code 
IIBSP-MIO-2015-66) in accordance with the Declaration of Helsinki for human research.
Cell cultures. Control muscle biopsies were obtained from subjects undergoing hip replacement surgery To 
obtain highly purified myoblasts, primary cultures were sorted for the early surface marker CD56 by immuno-
magnetic selection. Each 107 cells were mixed with 20 μL CD56-coated microbeads (Milteny Biotec, Bergisch 
Gladbach, Germany) and incubated at 4 °C for 15 minutes. Unbound microbeads were removed by washing cells 
in excess PBS buffer followed by centrifugation at 300 × g for 10 minutes. The cell pellet was resuspended in PBS 
buffer to a concentration of 2 × 108 cells/ mL before separation on a midiMACS cell separator (Milteny Biotec). 
Only cultures with more than 95% CD56 + myoblasts were used. The purity was tested by immunocytochemistry 
using anti-CD56 (Becton Dickinson Labware, Franklin Lakes, NJ) or anti-desmin antibodies (Leica, Wetzlar, 
Germany)31.
HEK-293 cell line was purchased from ATCC (Manassas, VA, USA) (CRL-1573) and cultured in DMEM 
medium supplemented with 5% FBS (Lonza, Basel, Switzerland), 5% of horse serum (Lonza), 1 mM of glutamine 
(Lonza), 1 mM of sodium pyruvate (Lonza) and antibiotics (Lonza).
Human myotubes were cultured under hypoxia (1%O2) in a H35 hypoxystation (Don Whitley Scientific Ltd., 
West Yorkshire, UK). Chemically-induced hypoxia was performed adding 250 µM of Cobalt (II) chloride hex-
ahydrate (CoCl2) to the culture medium (Sigma, St Louis, MO, USA). CoCl2 is a stabilizer of HIF-1α that mimics 
hypoxia responses32.
Myotubes were stimulated with 10 and 100 U/ml of IFN-α or IFN-β (Peprotech, Rocky Hill, NJ, USA) in 
normoxic conditions. Cells cultured in the different conditions were scraped and analyzed by western blot and by 
Real time PCR at different time points.
RNA extraction and Real Time PCR. Total RNA from cell samples was extracted using Trizol (Invitrogen, 
Thermo-Fisher Scientific, Waltham, MA, USA). A 0.5 μg of total RNA was DNAse treated (Invitrogen) and 
reverse-transcribed into cDNA using the high capacity cDNA RT kit (Life Technologies, Thermo-Fisher 
Scientific, Waltham, MA, USA). Quantification of the transcript corresponding to DDX58 (RIG-I) (Hs00204833_
m1) was performed using TaqMan Universal Master Mix technology (Life Technologies). Desmin was used as 
internal control (Hs00157258_m1) because its expression was stable in the different experimental conditions. 
Quantitative PCR was performed in a total reaction volume of 12 μl per well. The comparative Ct method (ΔΔCt) 
for relative quantification of gene expression was used.
Western-blot. 15 μg of protein were loaded into each lane. Blots were incubated with mAb mouse anti-RIG-I 
(Novus Biologicals, Littleton, CO, USA), pAb rabbit anti-HIF-1α (Novus Biologicals), rabbit anti-IRF3-P 
(Abcam, Cambridge, UK) and as a loading control mouse anti-β-actin (Sigma). Dye680 or Dye800 anti-mouse or 
anti-rabbit secondary antibodies (Li-Cor, Lincoln, NE, USA) were applied (1:7500). Immunoreactive bands were 
visualized using an Odyssey infrared image system and quantified using Odyssey Software (Li-Cor).
Immunofluorescence. Immunofluorescence was performed in 10 muscle biopsies of adult DM, in 10 
healthy control samples and in cultured cells.
Figure 7. Positive and negative controls for HIF-1α and RIG-I stainings. Human myotubes cultured with 
CoCl2 induce the translocation of HIF-1α to the nucleus. HEK-293 cells were transfected with pCMV-RIG-I. 
Magnification ×200.
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Double immunofluorescence was performed using a monoclonal rabbit anti-HIF-1α (1/25) (Abcam) and 
a monoclonal mouse anti-RIG-I (1/10) (Novus Biologicals) or anti-HIF-1α and a mouse anti-STAT1 (1/20) 
(BD Biosciences, Franklin Lakes, NJ). After washing, sections were incubated with biotinylated goat anti-rabbit 
(Vector Laboratories, Burlingame, CA, USA), followed by streptavidin Alexa-594 (Molecular Probes, Eugene, 
OR, USA) and goat anti-mouse 488 (1/200) (Molecular Probes). As positive controls we performed HIF-1α stain-
ing in human myotubes cultured with CoCl2 and RIG-I staining in HEK-293 cells transfected with pCMV-RIG-I. 
As a negative control, muscle sections and cells were incubated with the secondary antibodies only. Images were 
obtained using an Olympus BX51 microscope coupled to a DP72 camera.
IFN-β and IFN-α ELISA. Culture supernatants were concentrated using Amicon Ultra Centrifugal Filters 
10 K  (Merck Millipore, Darmstadt, Germany). IFN-β present in the culture media of myotubes exposed to 
hypoxia (1% of O2 and CoCl2-treated myotubes) was detected with VeriKine-HS Human IFN Beta Serum ELISA 
kit (PBL Assay Science, Piscataway Township, NJ), following manufacturer’s instructions. All samples were ana-
lyzed by triplicate. The limit of detection was 1.2 pg/ml. IFN-α in culture media was detected with VeriKine-HS 
Human IFN alpha ELISA kit (PBL Assay Science), the limit of detection was 12.5 pg/ml.
Construction of Luciferase reporter gene plasmids, directed mutagenesis, transient transfec-
tion and luciferase assays. For more details see methods and protocols as SI.
Statistics. T-test, two-way ANOVA, Tukey’s multiple comparisons test were performed. A value of p < 0.05 
was considered significant. GraphPad Prism 5.0 (GraphPad Software, San Diego, CA) was used for data elabora-
tion and statistical analysis.
Ethical approval. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional ethic committee (Hospital de la Santa Creu i Sant Pau,Code No. 
12/2009) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent. Informed consent was obtained from all individual participants included in the study.
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